Physician profile
Katherine Gray
NPI 1760687537
$632.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2022: $159.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $118.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.08 | 2019 | |
| Novo Nordisk INC | $75.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $72.83 | 2019-2022 | |
| Pfizer INC. | $64.54 | 2019 | |
| Amgen INC. | $56.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $44.16 | 2019 | |
| Lilly USA, LLC | $37.48 | 2019 | |
| Allergan, INC. | $19.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.16 | 2019 | |
| Shire North American Group INC | $12.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.